Last update: Aug. 24, 2019


Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Level of risk reviewed on Aug. 24, 2019

Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Es un aminoácido natural, precursor inmediato de la dopamina y con similares efectos a ella.
Indicado en el tratamiento de la enfermedad de Parkinson, en la que hay una falta de dopamina en el cerebro, donde actúa como neurotransmisor.
Para evitar los efectos periféricos de la levodopa al convertirse en dopamina (nauseas, vómitos, arritmias), la levodopa se asocia a carbidopa o a benserazida, que bloquean los enzimas periféricos que metabolizan la levodopa, y permiten que llegue más cantidad de levodopa al cerebro y se pueda dar a menor dosis.
Administración oral 3 a 4 veces al día.

Aunque los datos son limitados, la levodopa se excreta en leche materna en cantidad clínicamente no significativa, 100 veces inferior a la dosis utilizada en lactantes que lo precisan (Thulin 1998) y no se han observado problemas a corto o largo plazo en lactantes cuyas madres la tomaban (Thulin 1998).

La levodopa disminuye la secreción de prolactina (WHO 2002, Petraglia 1987, Nattero 1986, Linkowski 1983, Kaulhausen 1982, Rao 1982), pero el estímulo de la succión del lactante suele ser suficiente para asegurar la producción de leche materna; de hecho, una madre amamantó al menos 4,5 meses mientras continuaba el tratamiento (Thulin 1998). Otra madre, afecta de Parkinson de muy difícil control con infusión continua de levodopa intravenosa y gel de carbidopa en administración duodenal desde el embarazo, amamantó por tres meses: El desarrollo psicomotor del lactante fue normal, no así su peso que venía lastrado por una desnutrición intrauterina (Zlotnik 2014).

La carbidopa, que siempre se asocia a la levodopa, inhibe los efectos supresores de la levodopa sobre la prolactina (Camanni 1978).

La levodopa no impide la lactancia (Thulin 1998).

See below the information of this related product:


We do not have alternatives for Levodopa.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Levodopa is also known as

Levodopa in other languages or writings:


Levodopa belongs to this group or family:


Main tradenames from several countries containing Levodopa in its composition:

  • Carlevod™. Contains other elements than Levodopa in its composition
  • Cloison™. Contains other elements than Levodopa in its composition
  • Credanil™. Contains other elements than Levodopa in its composition
  • Dopar
  • Duodopa™. Contains other elements than Levodopa in its composition
  • Larodopa
  • Lebocar™. Contains other elements than Levodopa in its composition
  • Lecarge™. Contains other elements than Levodopa in its composition
  • Madopar
  • Nakom™. Contains other elements than Levodopa in its composition
  • Nervocur™. Contains other elements than Levodopa in its composition
  • Parkinel™. Contains other elements than Levodopa in its composition
  • Prikap™. Contains other elements than Levodopa in its composition
  • Racovel™. Contains other elements than Levodopa in its composition
  • Sinemet™. Contains other elements than Levodopa in its composition
  • Symblyopia (思利巴)
  • Ternovag™. Contains other elements than Levodopa in its composition


Variable Value Unit
Oral Bioavail. 70 %
Molecular weight 197 daltons
Protein Binding 10 - 30 %
VD 0,9 - 1,6 l/Kg
pKa 9,06 -
Tmax 0,5 - 2 hours
T1/2 1 - 1,5 hours
M/P ratio 0,2 - 0,3 -
Theoretical Dose 0,05 - 0,1 mg/Kg/d
Relative Dose 0,3 - 0,8 %


  1. Merck. Levodopa/Carbidopa (Sinemet). Drug Summary. 2018 Full text (in our servers)
  2. AEMPS - MSD. Levodopa/Carbidopa (Sinemet). Ficha técnica. 2017 Full text (in our servers)
  3. Zlotnik Y, Giladi N, Hilel A, Shapira Y, Goldstein S, Gurevich T. Levodopa-carbidopa intestinal gel (LCIG) infusion during pregnancy and delivery: first documented case. Parkinsonism Relat Disord. 2014 Nov;20(11):1317-8. Abstract
  4. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Full text (link to original source) Full text (in our servers)
  5. Thulin PC, Woodward WR, Carter JH, Nutt JG. Levodopa in human breast milk: clinical implications. Neurology. 1998 Jun;50(6):1920-1. No abstract available. Abstract
  6. Petraglia F, De Leo V, Sardelli S, Mazzullo G, Gioffrè WR, Genazzani AR, D'Antona N. Prolactin changes after administration of agonist and antagonist dopaminergic drugs in puerperal women. Gynecol Obstet Invest. 1987;23(2):103-9. Abstract
  7. Nattero G, Corno M, Savi L, Isaia GC, Priolo C, Mussetta M. Prolactin and migraine: effect of L-dopa on plasma prolactin levels in migraineurs and normals. Headache. 1986 Jan;26(1):9-12. No abstract available. Abstract
  8. Linkowski P, Brauman H, Mendlewicz J. Prolactin and growth hormone response to levodopa in affective illness. Neuropsychobiology. 1983;9(2-3):108-12. Abstract
  9. Rao R, Scommegna A, Frohman LA. Integrity of central dopaminergic system in women with postpartum hyperprolactinemia. Am J Obstet Gynecol. 1982 Aug 15;143(8):883-7. Abstract
  10. Kaulhausen H, Oney T, Leyendecker G. Inhibition of the renin--aldosterone axis and of prolactin secretion during pregnancy by L-dopa. Br J Obstet Gynaecol. 1982 Jun;89(6):483-8. Abstract
  11. Camanni F, Picotti GB, Massara F, Molinatti GM, Mantegazza P, Müller EE. Carbidopa inhibits the growth hormone- and prolactin-suppressive effect of L-dopa in acromegalic patients. J Clin Endocrinol Metab. 1978 Sep;47(3):647-52. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by AELAMA

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM